These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 22776989)
1. Bethesda criteria for microsatellite instability testing: impact on the detection of new cases of Lynch syndrome. Serrano M; Lage P; Belga S; Filipe B; Francisco I; Rodrigues P; Fonseca R; Chaves P; Claro I; Albuquerque C; Pereira AD Fam Cancer; 2012 Dec; 11(4):571-8. PubMed ID: 22776989 [TBL] [Abstract][Full Text] [Related]
2. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines. Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M Tumori; 2014; 100(3):315-20. PubMed ID: 25076244 [TBL] [Abstract][Full Text] [Related]
3. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers. Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164 [TBL] [Abstract][Full Text] [Related]
4. Comparison between universal molecular screening for Lynch syndrome and revised Bethesda guidelines in a large population-based cohort of patients with colorectal cancer. Pérez-Carbonell L; Ruiz-Ponte C; Guarinos C; Alenda C; Payá A; Brea A; Egoavil CM; Castillejo A; Barberá VM; Bessa X; Xicola RM; Rodríguez-Soler M; Sánchez-Fortún C; Acame N; Castellví-Bel S; Piñol V; Balaguer F; Bujanda L; De-Castro ML; Llor X; Andreu M; Carracedo A; Soto JL; Castells A; Jover R Gut; 2012 Jun; 61(6):865-72. PubMed ID: 21868491 [TBL] [Abstract][Full Text] [Related]
5. A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting. Ramsoekh D; Wagner A; van Leerdam ME; Dinjens WN; Steyerberg EW; Halley DJ; Kuipers EJ; Dooijes D Gut; 2008 Nov; 57(11):1539-44. PubMed ID: 18625694 [TBL] [Abstract][Full Text] [Related]
6. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer. Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581 [TBL] [Abstract][Full Text] [Related]
7. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. Piñol V; Castells A; Andreu M; Castellví-Bel S; Alenda C; Llor X; Xicola RM; Rodríguez-Moranta F; Payá A; Jover R; Bessa X; JAMA; 2005 Apr; 293(16):1986-94. PubMed ID: 15855432 [TBL] [Abstract][Full Text] [Related]
8. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome. Berginc G; Bracko M; Ravnik-Glavac M; Glavac D Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325 [TBL] [Abstract][Full Text] [Related]
10. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419 [TBL] [Abstract][Full Text] [Related]
11. Evaluating the performance of clinical criteria for predicting mismatch repair gene mutations in Lynch syndrome: a comprehensive analysis of 3,671 families. Steinke V; Holzapfel S; Loeffler M; Holinski-Feder E; Morak M; Schackert HK; Görgens H; Pox C; Royer-Pokora B; von Knebel-Doeberitz M; Büttner R; Propping P; Engel C; Int J Cancer; 2014 Jul; 135(1):69-77. PubMed ID: 24493211 [TBL] [Abstract][Full Text] [Related]
12. MLH1 promoter germline-methylation in selected probands of Chinese hereditary non-polyposis colorectal cancer families. Zhou HH; Yan SY; Zhou XY; Du X; Zhang TM; Cai X; Lu YM; Cai SJ; Shi DR World J Gastroenterol; 2008 Dec; 14(48):7329-34. PubMed ID: 19109866 [TBL] [Abstract][Full Text] [Related]
13. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Clendenning M; Sotamaa K; Prior T; Westman JA; Panescu J; Fix D; Lockman J; LaJeunesse J; Comeras I; de la Chapelle A J Clin Oncol; 2008 Dec; 26(35):5783-8. PubMed ID: 18809606 [TBL] [Abstract][Full Text] [Related]
14. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features. Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E Digestion; 2004; 69(3):166-76. PubMed ID: 15118395 [TBL] [Abstract][Full Text] [Related]
15. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358 [TBL] [Abstract][Full Text] [Related]
16. Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Ryan P; Mulligan AM; Aronson M; Ferguson SE; Bapat B; Semotiuk K; Holter S; Kwon J; Kalloger SE; Gilks CB; Gallinger S; Pollett A; Clarke BA Cancer; 2012 Feb; 118(3):681-8. PubMed ID: 21721000 [TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular detection of inherited colorectal cancers in northeast Italy: a first prospective study of incidence of Lynch syndrome and MUTYH-related colorectal cancer in Italy. Urso E; Agostini M; Pucciarelli S; Rugge M; Bertorelle R; Maretto I; Bedin C; D'Angelo E; Mescoli C; Zorzi M; Viel A; Bruttocao G; Ferraro B; Erroi F; Contin P; De Salvo GL; Nitti D Tumour Biol; 2012 Jun; 33(3):857-64. PubMed ID: 22278153 [TBL] [Abstract][Full Text] [Related]
18. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome. van Lier MG; Leenen CH; Wagner A; Ramsoekh D; Dubbink HJ; van den Ouweland AM; Westenend PJ; de Graaf EJ; Wolters LM; Vrijland WW; Kuipers EJ; van Leerdam ME; Steyerberg EW; Dinjens WN; J Pathol; 2012 Apr; 226(5):764-74. PubMed ID: 22081473 [TBL] [Abstract][Full Text] [Related]
19. Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation. Pinheiro M; Pinto C; Peixoto A; Veiga I; Lopes P; Henrique R; Baldaia H; Carneiro F; Seruca R; Tomlinson I; Kovac M; Heinimann K; Teixeira MR Br J Cancer; 2015 Aug; 113(4):686-92. PubMed ID: 26247575 [TBL] [Abstract][Full Text] [Related]
20. Effectiveness of each Bethesda marker in defining microsatellite instability when screening for Lynch syndrome. Sinn DH; Chang DK; Kim YH; Rhee PL; Kim JJ; Kim DS; Park CK; Kim JW; Yun SH; Lee WY; Chun HK; Rhee JC Hepatogastroenterology; 2009; 56(91-92):672-6. PubMed ID: 19621678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]